Alkeon Capital Management LLC Has $2.02 Million Stock Holdings in Alto Neuroscience, Inc. (NYSE:ANRO)

Alkeon Capital Management LLC reduced its position in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 49.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 477,101 shares of the company's stock after selling 457,803 shares during the period. Alkeon Capital Management LLC owned 1.77% of Alto Neuroscience worth $2,018,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Wells Fargo & Company MN boosted its holdings in Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock valued at $46,000 after acquiring an additional 3,139 shares during the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new position in Alto Neuroscience during the 4th quarter valued at about $74,000. Jane Street Group LLC boosted its stake in shares of Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock valued at $79,000 after purchasing an additional 7,783 shares during the last quarter. Rhumbline Advisers grew its position in shares of Alto Neuroscience by 24.4% during the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock worth $108,000 after buying an additional 5,008 shares during the period. Finally, Barclays PLC raised its stake in shares of Alto Neuroscience by 34.5% during the fourth quarter. Barclays PLC now owns 39,807 shares of the company's stock worth $168,000 after buying an additional 10,208 shares during the last quarter.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $2.43 on Friday. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience, Inc. has a 12-month low of $1.60 and a 12-month high of $17.55. The firm has a fifty day moving average of $2.56 and a 200-day moving average of $3.92. The firm has a market capitalization of $65.81 million, a price-to-earnings ratio of -0.96 and a beta of 2.16.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.09. On average, equities research analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ANRO. HC Wainwright began coverage on shares of Alto Neuroscience in a research note on Monday, April 7th. They issued a "buy" rating and a $10.00 price objective on the stock. William Blair restated an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.40.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

Want to see what other hedge funds are holding ANRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alto Neuroscience, Inc. (NYSE:ANRO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.